当前位置: 首页 >> 检索结果
9408. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.9409. Presumed Asymptomatic Carrier Transmission of COVID-19.
作者: Yan Bai.;Lingsheng Yao.;Tao Wei.;Fei Tian.;Dong-Yan Jin.;Lijuan Chen.;Meiyun Wang.
来源: JAMA. 2020年323卷14期1406-1407页
This study describes possible transmission of novel coronavirus disease 2019 (COVID-19) from an asymptomatic Wuhan resident to 5 family members in Anyang, a Chinese city in the neighboring province of Hubei.
9411. Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke: The EXTEND-IA TNK Part 2 Randomized Clinical Trial.
作者: Bruce C V Campbell.;Peter J Mitchell.;Leonid Churilov.;Nawaf Yassi.;Timothy J Kleinig.;Richard J Dowling.;Bernard Yan.;Steven J Bush.;Vincent Thijs.;Rebecca Scroop.;Marion Simpson.;Mark Brooks.;Hamed Asadi.;Teddy Y Wu.;Darshan G Shah.;Tissa Wijeratne.;Henry Zhao.;Fana Alemseged.;Felix Ng.;Peter Bailey.;Henry Rice.;Laetitia de Villiers.;Helen M Dewey.;Philip M C Choi.;Helen Brown.;Kendal Redmond.;David Leggett.;John N Fink.;Wayne Collecutt.;Thomas Kraemer.;Martin Krause.;Dennis Cordato.;Deborah Field.;Henry Ma.;Bill O'Brien.;Benjamin Clissold.;Ferdinand Miteff.;Anna Clissold.;Geoffrey C Cloud.;Leslie E Bolitho.;Luke Bonavia.;Arup Bhattacharya.;Alistair Wright.;Abul Mamun.;Fintan O'Rourke.;John Worthington.;Andrew A Wong.;Christopher R Levi.;Christopher F Bladin.;Gagan Sharma.;Patricia M Desmond.;Mark W Parsons.;Geoffrey A Donnan.;Stephen M Davis.; .
来源: JAMA. 2020年323卷13期1257-1265页
Intravenous thrombolysis with tenecteplase improves reperfusion prior to endovascular thrombectomy for ischemic stroke compared with alteplase.
9413. The Need to Improve the Clinical Utility of Direct-to-Consumer Genetic Tests: Either Too Narrow or Too Broad.
Direct-to-consumer (DTC) genetic testing for disease susceptibility is largely dominated by 2 extremes—narrow tests that only screen for a few variants and broad tests that include dozens of genes. These tests may lack clinical utility for consumers wanting to understand their disease risks. In the context of genetic testing, clinical utility refers to the ability of a test to generate results that can be used to reduce morbidity and mortality through the adoption of medical management strategies, including screening and surgery. Narrow and broad tests, however, lack clinical utility for different reasons. Narrow tests are often incomplete, and only include a limited number of relevant variants. Broad tests, by contrast, are concerning because they often include genes for which well-established risk estimates, medical management guidelines, or both may be absent.
|